The role of serum HER2 as an alternative to fluorescence in situ hybridization for HER2 in metastatic breast cancer.

被引：0
|
作者：
Kong, SY [1 ]
Kwon, Y [1 ]
Lee, DH [1 ]
Lee, JS [1 ]
Lee, ES [1 ]
Ro, J [1 ]
机构：
[1] Natl Canc Ctr, Goyang, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：48S / 48S
页数：1
相关论文
共 50 条
  • [31] Correlation between serum HER2 extracellular domain (HER2 ECD) levels and tumour size in early, advanced and metastatic breast cancer with HER2 overexpression
    Makino, H.
    Tengan, H.
    Tatsuda, K.
    Hashidate, H.
    Mio, K.
    Kiguchi, T.
    Yamazaki, M.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S114 - S115
  • [32] Serum HER2 extracellular domain before surgery compared with HER2 in breast cancer
    Zidan, J.
    Mzalbat, R.
    Sharabi, A.
    BREAST, 2015, 24 : S44 - S45
  • [33] Novel Alternative Splice Variants of HER2 in Invasive Breast Cancer.
    Assam, E. E.
    Rhodes, A.
    Ladomery, M.
    Harries, L.
    Sohail, M.
    CANCER RESEARCH, 2011, 71
  • [34] Prospective Validation and Characterization of HER2 Positive Circulating Tumor Cells in Patients with HER2 Negative Metastatic Breast Cancer.
    Olson, E. M.
    Flores, L. M.
    Najita, J. S.
    Curley, C.
    Jeong, J.
    Murray, K.
    Savoie, J. J.
    Winer, E. P.
    Krop, I. E.
    CANCER RESEARCH, 2011, 71
  • [35] Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer
    Yano, T
    Doi, T
    Ohtsu, A
    Boku, N
    Hashizume, K
    Nakanishi, M
    Ochiai, A
    ONCOLOGY REPORTS, 2006, 15 (01) : 65 - 71
  • [36] Comparison of fluorescence in situ hybridization (FISH) with immunohistochemistry (IHC) for detection of HER2/neu amplification/overexpression in breast cancer.
    Sun, G
    Morales, JS
    Wilz, S
    McKee, C
    Amberson, J
    Gersen, S
    AMERICAN JOURNAL OF HUMAN GENETICS, 2000, 67 (04) : 107 - 107
  • [37] Efficacy of HER2 inhibitors in metastatic breast cancer by discordance in HER2 amplification status between primary and metastatic breast cancer
    Van Raemdonck, E.
    Berteloot, P.
    Laenen, A.
    Han, S.
    Van Nieuwenhuysen, E.
    Salihi, R.
    Concin, N.
    Vergote, I.
    Floris, G.
    Wildiers, H.
    Punie, K.
    Neven, P.
    CANCER RESEARCH, 2019, 79 (04)
  • [38] A Validation Study of HER2 Immunohistochemistry Digital Imaging Analysis and its Correlation with HER2 Fluorescence In Situ Hybridization Results in Breast Carcinoma
    Hartage, Ramon
    Li, Aidan
    Hammond, Scott
    Parwani, Anil
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 1458 - 1459
  • [39] Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer
    Aurilio, Gaetano
    Sandri, Maria Teresa
    Pruneri, Giancarlo
    Zorzino, Laura
    Botteri, Edoardo
    Munzone, Elisabetta
    Adamoli, Laura
    Facchi, Giuseppina
    Cullura, Daniela
    Verri, Elena
    Rocca, Maria Cossu
    Zurrida, Stefano
    Iacovelli, Roberto
    Nole, Franco
    FUTURE ONCOLOGY, 2016, 12 (17) : 2001 - 2008
  • [40] A Validation Study of HER2 Immunohistochemistry Digital Imaging Analysis and its Correlation with HER2 Fluorescence In Situ Hybridization Results in Breast Carcinoma
    Hartage, Ramon
    Li, Aidan
    Hammond, Scott
    Parwani, Anil
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 1458 - 1459
12345